- Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between CSIRO and the Doherty Institute
- The latest round of results are from ongoing testing of its anti-infective drug R237 against SARS-CoV-2, the virus that causes COVID-19
- According to RCE, the results confirm and extend the findings from testing in February, which found R327 to be 99.9 per cent effective against SARS-CoV-2 at higher doses
- On the basis of these findings, Recce has been issued a qualified recommendation to proceed to stage two of the programme
Read the Full Article on The Market Herald here
Recce Pharmaceuticals (RCE) has reported further findings from...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
38.8¢ |
Change
0.003(0.65%) |
Mkt cap ! $112.0M | |||
| Open | High | Low | Value | Volume |
| 38.5¢ | 39.0¢ | 38.0¢ | $4.167K | 10.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 24610 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 49817 | 1 |
View Market Depth
| Last trade - 15.44pm 31/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |